5 полученные результаты
OBJECTIVE
Based on ethno-botanical information collected from diabetic patients in Cuba and firstly reported inhibition of PTP1B and DPPIV enzymes activities, Allophylus cominia (A. cominia) was identified as possible source of new drugs that could be used for the treatment of type 2 diabetes
BACKGROUND
Ethno-botanical information from diabetic patients in Cuba led to the identification of Allophylus cominia as a possible source of new drugs for the treatment of type 2 diabetes mellitus (T2-DM).
METHODS
Chemical characterization of the extracts from A. cominia was carried out using
The data presented in this article are related to the research article under the title "in vitro anti-diabetic activity of flavonoids and pheophytins from Allophylus cominia Sw. on PTP1B, DPPIV, alpha-glucosidase and alpha-amylase enzymes" (Semaan et al., 2017) [3]. This article defines the kinetics
The preliminary chemical characterization of the aqueous extract of Allophylus cominia (L.) Sw leaves was carried out by a phytochemical screening, the determination of the protein concentration by Lowry's method, as well as the composition of fatty acids and carbohydrates by gaseous chromatography
The aqueous extract of the Allophylus cominia (L) Sw (Sapindaceae) leaves has shown anti-diabetic, anti-obesity and anti-inflammatory properties. In the Caribbean region, it is typically used for the treatment of type-2 diabetes.
Considering the herb-drug interaction, the aim of this study was to